By Rishab Shaju and Ateev Bhandari (Reuters) -Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares ...

Heartflow, backed by private investment firm Bain Capital, said on Wednesday it was targeting a valuation of up to $1.46 ...

HeartFlow’s current products are HeartFlow Plaque analysis, which aims to provide clinicians with the ability to more ...

Medical technology company Heartflow said on Friday it was targeting a valuation of up to $1.32 billion in its U.S. initial ...

Heartflow (NASDAQ:HTFL), a MedTech firm backed by private equity firms including Bain Capital, climbed ~50% on its first ...

Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable ...

Backed by Bain Capital, the health technology startup makes 3D models of people's hearts to help diagnose diseases. Here's ...

Heartflow, a company involved in AI technology for coronary artery disease, went public on Friday under the ticker symbol HTFL, raising $316.7 million with its initial public offering. Late last week, ...

HeartFlow joins a group of medtechs planning to go public in 2025, including Medtronic’s new standalone diabetes business and ...

Heartflow has pumped up its IPO ambitions, raising its proposal into the vicinity of $300 million. | After first pricing its offering earlier this month, the AI-powered coronary diagnostic developer ...

Medtech firm Heartflow was valued at $2.27 billion on Friday, with its shares surging 47.4% in the Nasdaq debut, as the IPO market gathers momentum and outrides tariff worries. The shares opened at ...